65 / 100

Assoc. Prof. Dr. Bagher Seyedalipour | Biochemistry Award | Best Researcher Award

Biochemistry, University of Mazandaran, Iran

 

Assoc. Prof. Dr. Bagher Seyedalipour is a distinguished biochemist at the University of Mazandaran, specializing in protein engineering and proteomics. With a Ph.D. from Tehran University, he teaches and conducts advanced research on protein structures and gene manipulation techniques, especially using recombinant DNA. His laboratory focuses on creating therapeutic proteins, like luciferase and superoxide dismutase, exploring their functions and effects through site-directed mutagenesis. Dr. Seyedalipourā€™s work advances understanding of pathogenic mutations, contributing significantly to molecular biology and therapeutic biochemistry. šŸ”¬šŸ§¬

 

Publication Profile

Scopus

Orcid

Academic Background

Dr. Bagher Seyedalipour is an accomplished biochemist with a profound dedication to academic research and teaching. He has developed an extensive foundation in the field of biochemistry through his rigorous education and current academic pursuits at the University of Mazandaran.

Education and Qualifications

Dr. Seyedalipour’s academic journey began with a Bachelor of Science in Biology from Shahid Beheshti University, Tehran. He furthered his expertise with a Masterā€™s degree in Biochemistry from Tarbiat Modares University, followed by a Ph.D. in Biochemistry from the Institute of Biochemistry and Biophysics at Tehran University. His extensive training equips him with in-depth knowledge across biochemical sciences, particularly in protein engineering and molecular biology.

Teaching and Research Interests

Dr. Seyedalipour teaches courses on Biochemistry, Structure, Metabolism, and Advanced Molecular Biology for undergraduate and graduate students. His laboratory is primarily focused on Enzymology, Protein Engineering, and Proteomics, aiming to characterize and manipulate genes using recombinant DNA technology. His research highlights include the expression and production of therapeutic proteins, such as luciferase, superoxide dismutase, and uricase, where he applies site-directed mutagenesis for mutation analysis and to explore mutation-pathogenicity relationships.

Conclusion

Dr. Bagher Seyedalipour is a strong candidate for the Research for Best Researcher Award. His work in biochemistry, particularly his focus on protein engineering and pathogenic mutation analysis, stands out in its potential impact on therapeutic advancements and our understanding of molecular biology.

Publication Top Notes Ā 

  • šŸ§¬ “Mutation/metal deficiency in the electrostatic loop enhanced aggregation process in apo/holo SOD1 variants: implications for ALS diseases,” Ashkaran, F., Seyedalipour, B., et al. ā€“ BMC Chemistry (2024)
  • šŸ§¬ “Implications of ALS-Associated Mutations on Biochemical and Biophysical Features of hSOD1 and Aggregation Formation,” Mohammadi, S., Seyedalipour, B., et al. ā€“ Biochemical Genetics (2024), 1 citation
  • šŸ§¬ “GSTP1-A313G genetic polymorphism and the risk of preeclampsia in pregnant women: A study in the northern population of Iran,” Jalalian, E.J., Seyedalipour, B., et al. ā€“ Pregnancy Hypertension (2024)s
  • šŸ§¬ “1,4-Diol Hq (TBHQ) vs 1,4-dithiol (TBDT); simulation of safe antioxidant with a lower carcinogenic activity,” Mosavi, S.Z., Seyedalipour, B., et al. ā€“ Science Progress (2024)
  • šŸ§¬ “Exploring the anti-amyloid potential of salvianolic acid A against the ALS-associated mutant SOD1,” Waheed, Z.A., Seyedalipour, B., et al. ā€“ Molecular Simulation (2024), 1 citation
  • šŸ§¬ “Catharanthine, an anticancer vinca alkaloid: in silico and in vitro analysis of the autophagic system,” Gholami, F., Seyedalipour, B., et al. ā€“ Naunyn-Schmiedeberg’s Archives of Pharmacology (2024)
  • šŸ§¬ “Polyphenolic flavonoid compounds as inhibitors of aggregation in FALS-associated D101G SOD1 mutant,” Qassim, H.M., Seyedalipour, B., et al. ā€“ Computational Biology and Chemistry (2023), 4 citations
  • šŸ§¬ “Role of charged residues of the ā€œelectrostatic loopā€ of hSOD1 in aggregation under amyloidogenic conditions,” Mavadat, E., Seyedalipour, B., et al. ā€“ International Journal of Biological Macromolecules (2023), 6 citations
  • šŸ§¬ “A double point mutation of SOD1 targeting net charge promotes aggregation,” Mavadat, E., Seyedalipour, B., et al. ā€“ Biochimica et Biophysica Acta (2023), 5 citations
  • šŸ§¬ “Sensitive determination of urea in luciferin chemiluminescence system,” Nemati, A., Seyedalipour, B., et al. ā€“ Chemical Papers (2023), 1 citation

 

 

Bagher Seyedalipour | Biochemistry Award | Best Researcher Award

You May Also Like